

# Role of CtBP in Cancer: A Central Hub Connecting Growth, Migration and Death

DI LIJUN (狄利俊)



Faculty of Health Sciences, University of Macau

澳門大學健康科學學院

---

2023,10,28


# CtBP is a well-established co-repressor



Chinnadurai et al., Mol Cel 2009

Stankiewicz et al., BioMol Concepts 2014

# CtBP is a repressor of tumor suppressor genes




**BRCA1,  
SIRT4  
SREBF2  
RAD51  
CD24  
PALB2**

...

- Di et al., Nature comm 2013*  
*Di et al., Nature Str Mol Bio 2010*  
*Zhao et al., Oncogene 2019*  
*Hao et al., CCR 2017, 2018*  
*Hao et al., Theranostics, 2019*  
*Wang et al., Cell death Disease 2015*  
*Wang et al., Oncogenesis 2017*  
*Li et al., IJBS 2023*

Chinnadurai 2009 Cancer Research

# CtBP is a regulator of cell metabolism




## KEGG Mapper Search Result

Pathway (223) Brite (0) Module (110) Network (49) Disease (0)






Sort by the Network list

Show matched objects

- 06033 Glycine, serine and arginine metabolism (9)
- 06024 Valine, leucine and isoleucine degradation (6)
- 06030 Methionine metabolism (6)
- 06525 Ferroptosis (6) →
- 06026 Glutathione biosynthesis (5) →
- 06032 Lipoic acid metabolism (5)
- 06015 N-Glycan biosynthesis (4)
- 06027 Purine salvage pathway (4)
- 06010 Urea cycle (3)
- 06014 Sphingolipid degradation (3)
- 06016 Phenylalanine and tyrosine metabolism (3)
- 06020 beta-Oxidation in mitochondria (3)
- 06036 Lysine degradation (3)
- 06037 Histidine metabolism (3)
- 06322 TRH-TSH-TH signaling (3)
- 06463 Parkinson disease (3)







# CtBPs deletion enhances ferroptosis sensitivity





# CtBPs deletion enhances ferroptosis sensitivity






MDA-MB-468 (Lipid Peroxidation)




# Knockdown CtBP results in the oxidative stress of TNBC



# Loss of CtBPs represses anti-oxidative related pathway




# Low CtBP associates with the increased abundance of PUFA and PE



# Summary


- CtBP represses ferroptosis.
- CtBP increases GSH/GSSG ratio.
- How CtBP regulates the genes involved in ferroptosis regulation is still under investigation.



# CtBP, a therapeutic Target?

Name of the compound	Structure of compound	Mode of action
MTOB 2-Keto-4-(methylthio)butyric acid		Substrate at low concentrations, but dehydrogenase inhibitor at high concentrations. <sup>86,88</sup>
HIPP derivatives (2-Hydroxyimino-3-phenyl-propionic acid)		Dehydrogenase inhibitors. <sup>82,89</sup>
Cyclic Peptide CP61 (cyclo-SGWTVVRYM)		Inhibitor of homo/ hetero-dimerization of CtBP1 and CtBP2. <sup>92</sup>
NSC95397		Inhibitor of CtBP interaction with partners such as E1A that contain PxDLS sequences. <sup>93</sup>

*Cancer Biol Ther.* 2017 Jun 3;18(6):379-391.



Bellesis et al. *JBC* 2018  
Jacrosi et al. *Structure* 2021

## Current lab members

Tai Lixin PhD

Li Jiajia

**Wang lifen**

Tang ping

Zhu Dongliang

Xu Hongxia

**Liu Tianyu**

Dr. Li Wang (Senior  
Instructor, Manager of  
Metabolomics core)

## Lab Alumni

Hao Dapeng, PhD

Zhao Zhiqiang, PhD

Li jingjing, PhD

Li Peipei, PhD

Wang Yuan PhD

## Acknowledgement

### Collaborators

*Benjamin Tsang, University of Ottawa*

*Shuhai Lin, Xiamen University*

*Haisheng Zhou, Anhui Medical University*

*Chuxia Deng, University of Macau*



科學技術發展基金  
FIDCIT

